①egfr抑制剂：激活ras突变对上游的egfr或rtk阻断具有结构性抵抗力。随着kras抑制剂的出现，人们对用kras抑制剂双重阻断rtk或egfr也有一些研究实验。 ②sos1抑制剂：当ras在“开”和“关”状态之间穿梭时，它很容易因抑制其上游的sos1而失活。

肿瘤表皮生长因子受体(EGFR)是一个170KDa的跨膜糖蛋白受体酪氨酸激酶，由表皮生长因子激活，影响细胞的生长和分化。 EGFR 家族又称为EGFR酪氨酸激酶家族，由4个不同的受体酪氨酸激酶(PTK)组成，分别为‍EGFR(HER-1/ErbB-1)、ErbB-2(HER-2/neu)、ErbB-3(HER-3) …

The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have become essential components in the treatment of patients …

2023年4月5日 · Through a drug-anchored synthetic lethality screen, we discovered that epidermal growth factor receptor (EGFR) inhibition was synthetic lethal with MRTX1133. Mechanistically, MRTX1133 treatment...

Epidermal growth factor receptor (EGFR) signaling pathways leading to G1/S cell cycle progression activated by EGF activation. Depicted are the RAS-RAF-MEK-ERK MAPK and PI3K-AKT-mTOR pathways. EGF activation of the EGFR induces receptor dimerization and transphosphorylation of the C-terminal domain.

2008年1月1日 · Here we highlight one important aspect of EGFR signaling, the bi-directional interaction between EGFR and Ras. We discuss the mechanistic basis for this interaction, its implications for cell biology, and its potential importance as a target for cancer therapy.

To tackle drug resistance, designing allosteric fourth-generationEGFR inhibitors is vital. Covalent, allosteric, or combinationaltherapies, along with PROTAC degraders, are key methods to addressresistance and toxicity in KRAS and BRAF inhibitors.

2023年11月27日 · EGFR下游信号通路： 1、Ras/Raf/MEK/ERK (MAPK) 通路. EGFR的磷酸化吸引并激活了Grb2和SOS蛋白。 SOS进一步激活了Ras蛋白。 活化的Ras激活Raf。 Raf激活MEK，MEK随后激活ERK。 ERK可以进入细胞核，调节多种基因的转录，进而影响细胞增殖、分化和生存。 2、PI3K/Akt (mTOR) 通路

This review presents an overview of recent findings on various epigenetic and post-transcriptional modifications of the epidermal growth factor receptor (EGFR), which activates the oncogenes RAS and MYC. Alterations in EGFR, RAS, and MYC play a crucial role in dysregulated processes that contribute to oncogenesis.

表皮生长因子受体 (Epidermal growth factor receptor，EGFR) 是受体酪氨酸激酶家族 (receptor tyrosine kinase family，RTK) 中第一个被发现的原型成员。 它被细胞外环境中的各种配体激活并传递细胞响应以介导各种细胞活动，包括细胞增殖、细胞存活、生长和发育。